• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Embecta stock soars on first full-quarter results after BD spinoff

August 15, 2022 By Jim Hammerand

BD Diabetes Spinoff EmbectaEmbecta (Nasdaq: EMBC) today posted third-quarter results today for the first time as a BD (NYSE: BDX) spinoff, beating the consensus forecast on Wall Street.

The Parsippany, New Jersey-based diabetes technology company reported profits of $62.4 million, or $1.08 per share, on sales of $291.1 million for the three months ended June 30.

RELATED: How Embecta is ‘uniquely positioned’ in diabetes space following spinoff from BD

Profits were down by 40%, and sales growth decreased 1.3% compared with Q3 2021, but the company said its first quarterly financial results as an independent entity “are not meaningfully comparable” to the time before Embecta spun off on April 1.

“Financial results during the pre-spin period were presented on the carve-out basis of accounting and do not purport to reflect what Embecta’s financial results would have been had Embecta operated as a standalone public company,” the company said in a news release.

Earnings were ahead of the Street, where analysts were looking for EPS of $0.87 on sales of $276.86 million.

“Our fiscal third quarter 2022 results reinforce our core strength and further position Embecta towards creating a company that allows for a life unlimited by diabetes,” Embecta CEO Devdatt “Dev” Kurdikar said in the news release. “Despite a challenging macro-economic environment, we delivered resilient commercial performance during our first quarter as an independent company.

In April, CFO Jake Elguicze said the company would bring in around $1.1 billion in annual revenue.

In May, the company reported $563.8 million worth of sales for the first half of the year. And today, Embecta maintained its guidance of approximately $555 million in second-half revenue.

“While we continue to navigate through supply chain and inflationary pressures, as well as certain COVID-19 restrictions,” Kurdikar said, “given the strength of our third quarter results, coupled with our outlook for the remainder of the fiscal year, we are reiterating our second half of 2022 fiscal year financial guidance for as-reported revenue growth, and raising our second half of 2022 fiscal year financial guidance for constant currency revenue growth, adjusted gross margin and adjusted EBITDA margin.”

Investors reacted by sending EMBC shares up more than 17% to $33.75 apiece in late afternoon trading. Our MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was relatively flat on the day.

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Uncategorized, Wall Street Beat Tagged With: BD, Diabetes, embecta

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Jim Hammerand

Jim Hammerand is the managing editor of Medical Design & Outsourcing. He has more than 15 years of professional journalism experience spanning newspapers, magazines, websites and broadcast news. For nearly a decade, he reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then managing editor of the Puget Sound Business Journal in Seattle. He holds a bachelor’s degree in journalism from the University of Minnesota. He is based near Seattle in Edmonds, Washington, where he and his family live. Connect with him on LinkedIn or by email at jimhammerand@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS